PT  - JOURNAL ARTICLE
AU  - Recoquillon, Sylvain
AU  - Pépin, Jean-Louis
AU  - Vielle, Bruno
AU  - Andriantsitohaina, Ramaroson
AU  - Bironneau, Vanessa
AU  - Chouet-Girard, Frédérique
AU  - Fleury, Bernard
AU  - Goupil, François
AU  - Launois, Sandrine
AU  - Martinez, M Carmen
AU  - Meslier, Nicole
AU  - Nguyen, Xuan-Lan
AU  - Paris, Audrey
AU  - Priou, Pascaline
AU  - Tamisier, Renaud
AU  - Trzepizur, Wojciech
AU  - Gagnadoux, Frédéric
TI  - Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: a randomised controlled trial
AID  - 10.1136/thoraxjnl-2018-212609
DP  - 2019 May 01
TA  - Thorax
PG  - 496--499
VI  - 74
IP  - 5
4099  - http://thorax.bmj.com/content/74/5/496.short
4100  - http://thorax.bmj.com/content/74/5/496.full
SO  - Thorax2019 May 01; 74
AB  - Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea–Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night).Trial registration number NCT01426607.